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Epilepsy is the most common neurological disorder in childhood which often requires long-term or sometimes lifelong treatment. Sodium valproate or valproic acid 
(VPA) is a broad-spectrum antiepileptic drug and one of the most 
commonly used antiepileptics in childhood. As VPA is used for 
prolonged periods in the management of seizures, it is important 
to monitor patients in terms of its potential adverse effects. 
Many antiepileptic drugs such as carbamazepine, phenytoin, and 
phenobarbitone have been associated with thyroid dysfunction, 
but the association with VPA is controversial.
There are conflicting results in clinical trials on the possible role 
of VPA in affecting the thyroid function in children [1-7]. Moreover, 
the age of the child, total daily dose, duration of VPA treatment, 
and serum levels of drug have been implicated as potential risk 
factors for the development of subclinical hypothyroidism [5,7]. 
Undiagnosed and untreated hypothyroidism in children can have 
harmful effects on the growth, school performance, and the pubertal 
development [8]. Therefore, the main objective of our study was 
to assess the effect of VPA monotherapy on thyroid function on 
short-term follow-up in children with newly diagnosed epilepsy.
METHODS
This was a prospective case–control study conducted at a tertiary 
care teaching institute from Western Maharashtra, India, during 
the period of June 2014–May 2016. Ethical committee clearance 
was taken before the commencement of the study. Children were 
recruited after obtaining a written consent from the parents. 
Inclusion criteria were children aged 1–12 years with newly 
diagnosed epilepsy who were started on VPA monotherapy, not 
on any other antiepileptics before the enrollment, with normal 
development, normal neurological examination, and normal 
thyroid function. Children with clinical suspicion of thyroid 
dysfunction or with family history of thyroid illness, children with 
congenital anomalies, and those on polytherapy for epilepsy were 
excluded from the study. Based on the number of patients with 
new onset epilepsy seen in our pediatric neurology OPD over a 
period of the past 1 year and considering the dropout rate of 5%, 
the sample size was calculated as 55 using the formula n=Z2pq/d2.
The control group consisted children with similar age and 
sex with normal development and no seizures. The control group 
was selected from the children visiting the pediatric outpatient 
department for any other complaints belonging to the same 
geographic area and similar lifestyle patterns as compared to the 
children in the study group. The sociodemographic details along 
with detailed seizure history were documented as per structured 
clinical pro forma. Standard charts and screening tools such as 
Trivandrum Development Screening tool and Vineland Adaptive 
Behavioral scales were used for the assessment of development 
and neurological examination. Seizure was classified as per the 
ILAE 2010 classification. New onset epilepsy was defined as 
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two or more unprovoked seizures more than 24 h apart. Detailed 
clinical examination of all children was done to rule out any 
abnormal neurological findings and to rule of any signs and 
symptoms of thyroid dysfunction. The same pediatric neurologist 
was involved in the initial assessment, follow-up, and the 
interpretation of electroencephalography (EEG).
EEG was done for all the subjects in the case group in the 
same institute and neuroimaging as indicated. A baseline thyroid 
function was done in all the children - both cases and controls. 
Once the diagnosis of epilepsy was established, based on the 
clinical history and EEG findings, oral VPA therapy was started 
in a dosage of 15–20 mg/kg/day in two divided doses. The serum 
VPA levels were estimated at 72 h and 6 months of the initiation 
of therapy. The therapeutic blood level of VPA was considered as 
50–125 µg/mL. Repeat clinical examination for the signs of thyroid 
dysfunction was done at 3 months and 6 months of follow-up.
Thyroid function - serum T3, T4, and thyroid-stimulating 
hormone (TSH) - was done in all children during enrollment, then 
at 3 months, and 6 months in case group and at 6 months in control 
group. The blood samples for thyroid function test were collected 
in the fasting state between 8 am and 10 am and were assessed 
using Chemi-Lumina illumination method at the Central Clinical 
Laboratory. Normal levels of thyroid hormones (reference ranges 
of serum T3 - 0.87–1.78 ng/ml, serum T4 - 6.09–12.23 ug/dL, and 
serum TSH - 0.35–5.5 μIU/mL) were used from our laboratory. 
Subclinical hypothyroidism was defined as the presence of an 
elevated level of TSH (>5.5 μIU/mL), with normal concentrations 
of serum T4 and T3. Overt hypothyroidism was defined as having 
an elevated TSH level of  >10 μIU/mL and decreased T4 and T3 
levels. Baseline hemogram and liver function test were done in all 
children started on valproate.
Data were expressed as mean±standard deviation values. 
Statistical analysis was done using the Statistical Package for the 
Social Science Version 17, and repeated measure test (ANOVA) 
was used as a test for statistical significance; p<0.05 was 
considered as statistically significant.
RESULTS
Sixty-two children with new onset epilepsy attending the 
pediatric neurology OPD were approached, of which three parents 
declined the consent, and four children needed to start on other 
AEDs before they could get enrolled in the study. Therefore, 55 
children, who fulfilled the inclusion criteria, were finally enrolled 
in the study group. The control group consisted of 55 age- and 
sex-matched children with normal development and no seizures. 
The characteristics of the subjects in both study and control 
group are summarized in Table 1. Of 55 children with epilepsy, 
27 (49%) children were in the age group of 1–3 years. Most of the 
children (45.5%) had the onset of seizures in the same age group 
(1–3 years). Only two children had a family history of epilepsy. The 
mean serum VPA levels were 57.0±13.01 µg/ml at baseline and 
80.92±17.44 µg/ml at 6 months that showed increasing trend but 
were within in therapeutic reference range during the study period. 
The most common type of seizure was generalized (51 cases), of 
which 46 children had generalized tonic-clonic convulsions.
Table 2 summarizes the thyroid function tests done at baseline 
and follow-up values in both groups. Baseline thyroid function test 
was comparable in both the groups. On follow-up at 6 months, 12 
of 55 children (21.8%) showed subclinical hypothyroidism with 
elevated TSH levels, which was statistically significant (p=0.003) 
and normal T3 and T4 levels. The control group did not show 
any significant change in thyroid hormone levels at 6 months of 
follow-up compared to baseline levels.
Table 3 demonstrates the comparison of thyroid function test 
between VPA group and control group. T3 levels in VPA group 
showed higher levels compared to control group, but levels were 
within normal range. TSH levels showed a significant increase in 
VPA group compared to control group (p=0.015).
There was no statistically significant correlation between 
the serum VPA levels and the thyroid function at 6 months of 
follow-up (Spearman’s rho value 0.114; p=0.20).
DISCUSSION
Adverse effects of antiepileptic drugs are common, and the 
profile includes cognitive impairment, coordination difficulties, 
sedation, behavioral abnormalities, and endocrine dysfunction. 
Derangement in thyroid function has been demonstrated with 
carbamazepine, oxcarbazepine, and phenobarbital by various 
studies [3,4,6,9-11], but the association with VPA remains 
Table 1: Characteristics of subjects
Parameters Cases Control
Mean age 4.78±3.3 4.84±3.18
1–3 years 27 (49) 24 (43.63)
4–6 years 16 (29) 18 (32.7)
7–9 years 4 (7.2) 6 (10.9)
10–12 years 8 (7.27) 7 (12.7)
Gender
Males 27 (49.1) 29 (52.7)
Females 28 (50.9) 26 (42.2)
Age of onset of seizures
≤1 year 12 (21.8) -
1.1–3 year 25 (45.45) -
3.1–6 8 (14.55) -
>6 10 (18.18) -
Serum valproate acid 
levels (µg/ml)
Baseline 57.0±13.01
6 months 80.92±17.44
Type of seizures
Generalized 51 (92.7) -
GTCS 46 (83.63) -
Myoclonic 4 (7.27) -
Absence 1 (1.82) -
Focal 4 (7.27) -
GTCS: Generalized tonic-clonic seizure
Malwade et al. Valproic acid and suclinical hypothyroidism in children
Vol 5 | Issue 4 | Apr 2018 Indian J Child Health 233
controversial [12,13]. It has been demonstrated that even 
subclinical hypothyroidism during childhood may cause growth 
and developmental disorders, cognitive impairment, and subtle 
neuromuscular abnormalities [14-16]. VPA is well known for its 
broad-spectrum antiepileptic activity, excellent tolerance, absence 
of sedative action, and no effect on cognition [8]. Therefore, it is 
widely used for control of many types of epilepsies and epileptic 
syndromes in children.
The present study showed the trend of rising TSH levels on 
VPA monotherapy at 6 months of follow-up that was statistically 
significant (p<0.05). Similar results were obtained by previous 
studies [1-3,5,7,8,17-20] but not in all studies [12,13]. All the 
subjects remained asymptomatic during the follow-up period. 
Measurement of serum TSH level is considered as the most reliable 
in evaluating the true thyroidal state of patients taking antiepileptic 
drugs [1,17]. Of 55 children, 12 out of 55 (21.8 %) subjects 
showed subclinical hypothyroidism. The incidence of subclinical 
hypothyroidism in our study seems to be low (21.8% - 12/55) 
as compared to Kim et al. [5] (52.4% - 32/61), Eris – Punal [2] 
(25.5% - 13/51), and Mikati [7] (25.1% - 36/143).
Several well-conducted studies have identified various risk 
factors for subclinical hypothyroidism in VPA monotherapy 
patients including younger age, duration of treatment between 
6 months and 24 months, VPA levels [5], and polytherapy [7]. Our 
study group showed more incidence of subclinical hypothyroidism 
in younger age group (1–3 years) which was consistent with the 
study by Mikati et al. and Cansu et al. [3,7]. Furthermore, few 
authors have reported no significant impact of age on subclinical 
hypothyroidism in patients with VPA monotherapy [5,18,20,21].
We found the onset of subclinical hypothyroidism at 6 months 
of duration of treatment, which was in agreement with the 
majority of studies that have demonstrated onset of subclinical 
hypothyroidism at 1 month [19], 6 months, 12 months, and 
24 months [1,3,7,10,22]. In contrast, some authors have shown no 
effect on length of the treatment on TSH levels [5,9]. The effect 
of VPA on thyroid hormone may be transient and lasts as long as 
drug is continued. Attilakos et al. [1] and Vainionpaa et al. [17] 
have demonstrated restoration of thyroid function after VPA 
discontinuation.
The seizures were well controlled during the study period in 
all the subjects, and even though dose adjustment was done, up to 
40 mg/kg/day in few patients, serum VPA levels were maintained 
in therapeutic range only. We found no correlation between VPA 
serum levels and subclinical hypothyroidism (p=0.20) which 
was in congruent with many of the studies [1,7,9,18,20]. To the 
best of our knowledge, there is only one study which identified 
a positive correlation between VPA levels and subclinical 
hypothyroidism [5]. Kim et al. [5] demonstrated that 32 children 
with subclinical hypothyroidism had elevated serum VPA levels.
The current understanding of the pathogenesis of subclinical 
hypothyroidism and VPA monotherapy is unclear. The possible 
mechanisms suggested are interference with the secretion, 
metabolism, or feedback regulation of TSH through its 
GABAergic properties [23] and deficiencies of zinc and selenium 
which could contribute to subclinical hypothyroidism [24,25].
Limitations of our study are small sample size and short 
duration of follow-up. It was difficult to have a control group 
of children with epilepsy without treatment with obvious ethical 
reasons. There is evidence that body mass index can influence 
thyroid function test which we have not evaluated. However, 
this study has highlighted the trend toward rising TSH levels in 
valproate monotherapy at 6 months.
CONCLUSION
We found a positive correlation between subclinical 
hypothyroidism and VPA monotherapy which can occur early 
in the course of treatment. Therefore, it would be prudent to 
measure serum thyroid hormones routinely in children treated 
with VPA. Although there is no consensus on frequency of 
measurement of thyroid function while on VPA treatment, based 
Table 2: Comparison of thyroid function test
Study 
Population
Thyroid 
function
Baseline (n=55) At 3 months (n=55) At 6 months (n=55) t value p value
Mean SD Mean SD Mean SD
VPA group T3 (ng/ml) 1.25 0.43 1.22 0.64 1.22 0.33 0.64 0.53
T4 (µg/dl) 8.54 2.37 7.83 1.98 8.41 1.97 0.49 0.62
TSH (mIU/ml) 3.21 1.80 3.12 1.53 4.13 2.03 3.10 0.003
Control group T3 (ng/ml) 1.07 0.26 - - 1.07 0.26 1.16 0.25
T4 (µg/dl) 7.99 2.19 - - 8.31 2.02 1.41 0.16
TSH (mIU/ml) 3.31 1.29 - - 3.32 1.32 0.07 0.95
VPA: Valproic acid, TSH: Thyroid-stimulating hormone
Table 3: Comparison of thyroid function test between cases and 
controls
Thyroid 
function
Case Control p value
T3
Baseline 1.25±0.43 1.03±0.25 0.001
6 months 1.22±0.33 1.07±0.26 0.011
T4
Baseline 8.54±2.37 7.99±2.19 0.22
6 months 8.41±1.97 8.31±2.02 0.78
TSH
Baseline 3.21±1.80 3.31±1.29 0.72
6 months 4.13±2.03 3.32±1.32 0.015
TSH: Thyroid-stimulating hormone
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on few good clinical studies, it can be advocated to do at every 
3 month. Further, prospective studies are needed to demonstrate 
the association between daily dose, VPA serum concentration, 
age and subclinical hypothyroidism, as well as possible role of 
ethnicity and geography.
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